鼻窦炎临床试验的趋势与改进方向分析
该研究基于ClinicalTrials.gov数据库,分析了1993至2017年间269项鼻窦炎临床试验,旨在描述试验趋势、提示冗余并提出治疗方向建议。结果显示51.7%的试验有至少一篇科学发表,其中80.6%为阳性结果;药物试验中许多针对同一药物,药物干预试验稳步下降而手术干预试验上升。
要点
- 鼻窦炎临床试验中手术干预比例上升,药物干预比例下降。
- 许多药物试验集中于相同药物,存在冗余。
- 仅51.7%的试验有科学发表,发表试验中80.6%为阳性结果。
核心结论
- 该分析首次刻画鼻窦炎临床试验特征,揭示某些药物过度代表并显示手术干预试验增加。
研究设计与样本
- 数据库分析,数据来自ClinicalTrials.gov,纳入1993至2017年269项鼻窦炎临床试验,排除入组前撤回的试验。
主要发现
- 51.7%的试验有至少一篇科学发表,发表试验中80.6%为阳性结果、19.3%为阴性结果。
- 药物试验数据显示许多临床试验研究同一药物,且药物干预试验稳步下降而手术干预试验上升。
临床怎么用
- 为未来鼻窦炎研究优先级的讨论提供框架,以指导临床和研究实践。
局限性
- 证据等级为4。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: To characterize trends in rhinosinusitis clinical trials to provide recommendations for therapeutic directions, highlight possible redundancy, and provide a framework for prioritization of future clinical trials. STUDY DESIGN: Database analysis. METHODS: Data were collected from ClinicalTrials.gov including all clinical trials that focused on rhinosinusitis with the exclusion of trials withdrawn prior to enrollment. Variables recorded included study design, study population, pharmaceutical involvement, publication, and whether a trial was a medical or surgical intervention. Associated publications were identified using the PubMed, Embase, and Cochrane databases. RESULTS: There were 269 rhinosinusitis clinical trials, dating from 1993 to 2017, that met inclusion reauirements. Of the studies included in this analysis, 51.7% had at least one scientific publication, and of those with publications, 80.6% had positive results and 19.3% had negative results. Twenty-three clinical trials (8.5%) studied drugs already approved for rhinosinusitis, 113 (42.0%) trials studied drugs that were approved for other uses, 42 (15.6%) trials studied experimental drugs, and 102 (39.4%) studied surgical intervention. Of the trials studying drugs, the data showed many clinical trials that studied the same drug. The data demonstrate a steady decline in clinical trials with medical intervention and a rise in clinical trials with surgical intervention. CONCLUSIONS: This analysis is the first to characterize rhinosinusitis clinical trials, highlighting the over-representation of certain drugs and demonstrating an increased focus on clinical trials employing surgical intervention. We provide a framework to discuss prioritization of future studies to guide clinical and research practice. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:1281-1286, 2018.
引用
- Ramsey T, Lai W, Guo E, et al. Clinical trials in rhinosinusitis: Identifying areas for improvement. Laryngoscope. 2017. PMID: 29105773. doi:10.1002/lary.26912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。